Journal of the American Geriatrics Society, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 7, 2025
ABSTRACT The Inflation Reduction Act (IRA) of 2022 introduced major changes in the Part D benefit that aim to improve medication access and correct several financial misalignments current benefit. address obligations Medicare beneficiaries, federal government, plan sponsors (i.e., insurance companies), drug manufacturers. include new brand biologic manufacturer beneficiaries eligible for low‐income subsidy. Effects on supply chain stakeholder behaviors remain be seen but arrangements inform likely responses. Currently, Pharmacy Benefit Managers (PBMs) nestled between plans, manufacturers, pharmacies heavily influence manufacturers' list prices squeeze community pharmacies. With IRA restructuring D, plans are interject more administrative obstacles before can obtain higher‐cost therapies, while manufacturers might alter their patient assistance programs. Manufacturers have already begun change programs at many safety net Many who relied these deeply discounted medications will face significant late enrollment penalties if they do enroll creating a barrier participation. Providers policymakers should understand leverage skills pharmacists support team‐based care improves ensures doing good than harm.
Language: Английский